Supernus Pharmaceuticals, Inc.
SUPNHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 5, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Supernus Pharmaceuticals, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United. With a market capitalization of $2.53B, it sits in mid-cap territory. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Market Cap
$2.53B
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
9.76
EPS (TTM)
$-1.90
EPS (Fwd)
$4.46
ROE
-10.5%
ROA
0.4%
Cash
$372.1M
Total Debt
$40.2M
Free CF
$84.6M
52W Change
-4.0%
Annual Financials
Cash vs Debt
Where SUPN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, SUPN finished 10.06% below its 150-day moving average ($48.63) and 9.85% below its 200-day moving average ($48.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SUPN overbought or oversold?
At the September 2, 2026 close, SUPN's RSI(14) was 27.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $372.1M in cash and $40.2M in debt, SUPN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $84.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -10.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.4% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $667.2M (2022) to $719.0M (2025).
The relatively low beta of 0.56 suggests SUPN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, SUPN has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing SUPN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.